United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $236.47, for a total transaction of $851,292.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $30,741.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
United Therapeutics Trading Up 1.1 %
Shares of NASDAQ:UTHR opened at $237.00 on Thursday. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The company’s fifty day simple moving average is $232.93 and its 200 day simple moving average is $228.74. The firm has a market cap of $11.15 billion, a price-to-earnings ratio of 11.95 and a beta of 0.52.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The firm’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.67 earnings per share. As a group, research analysts forecast that United Therapeutics Co. will post 23.76 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several equities research analysts have weighed in on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wells Fargo & Company increased their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and increased their target price for the stock from $213.00 to $215.00 in a report on Monday, February 12th. Wedbush restated an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $294.25.
View Our Latest Research Report on UTHR
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Five stocks we like better than United Therapeutics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- High-Yield Texas Instruments Could Hit New Highs Soon
- What is the Nikkei 225 index?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What is a Dividend King?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.